Ilene Galinsky, BSN, MSN, ANP-C, senior leukemia protocol research nurse practitioner, at Dana Farber Cancer Institute, discusses how treatment for patients with acute myeloid leukemia has evolved in recent years.
Ilene Galinsky, BSN, MSN, ANP-C, senior leukemia protocol research nurse practitioner, at Dana Farber Cancer Institute, discusses how treatment for patients with acute myeloid leukemia (AML) has evolved in recent years.
It is a very exciting to be a nurse or nurse practitioner in oncology, Galinksy explained, especially with the advances in therapeutics for patients with AML. These novel therapies are now less toxic compared with 7+3 chemotherapy, which patients would previously receive regardless of their molecular makeup.
The evolution in science has also led to identification of molecular abnormalities and ways to target these aberrations through treatment, Galinsky explains. These precision medicine approaches have led to improvements in overall survival as well as quality of life, she concludes.
Shared Model of Care Post-HCT Offers Safe Follow-Up, Reduces Patient Burden
Published: March 19th 2025 | Updated: March 19th 2025Alternating post-HCT care between specialized facilities and local cancer centers produced noninferior non-relapse mortality and similar quality of life to usual care.